

CITATION REPORT

List of articles citing

Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease

DOI: 10.1016/s0002-9149(99)00117-4
American Journal of Cardiology, 1999, 83, 1303-7.

Source: <https://exaly.com/paper-pdf/30566253/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
230	From Clinical Research to Clinical Practice: Closing the Gap. 1999 , 34, 12-16		
229	Dyslipidemia and atherosclerosis: how much more evidence do we need?. 1999 , 10, 383-6		4
228	Bibliography. Current world literature. Cardiac failure. 2000 , 15, B95-136		
227	A novel telephone-based system for management of secondary prevention to a low-density lipoprotein cholesterol American Journal of Cardiology, 2000 , 85, 305-8	3	35
226	A symposium: lipid management summit on improving practice outcome. Introduction. <i>American Journal of Cardiology</i> , 2000 , 85, 1A-2A	3	1
225	Rationale and design of the Cardiac Hospitalization Atherosclerosis Management Program at the University of California Los Angeles. <i>American Journal of Cardiology</i> , 2000 , 85, 10A-17A	3	58
224	Lipid management in a private cardiology practice (the Midwest Heart experience). <i>American Journal of Cardiology</i> , 2000 , 85, 18A-22A	3	30
223	Secondary prevention in a cardiology group practice and hospital setting after a heart-care initiative. <i>American Journal of Cardiology</i> , 2000 , 85, 23A-29A	3	13
222	Optimizing treatment of dyslipidemia in patients with coronary artery disease in the managed-care environment (the Rocky Mountain Kaiser Permanente experience). <i>American Journal of Cardiology</i> , 2000 , 85, 36A-42A	3	28
221	Improving patient outcomes by pooling resources (the Texas Heart Care Partnership experience). <i>American Journal of Cardiology</i> , 2000 , 85, 43A-51A	3	6
220	Quality assessment and lipid management: considerations for computer databases for tracking patients. <i>American Journal of Cardiology</i> , 2000 , 85, 52A-56A	3	3
219	Effects of age, sex, race, diagnosis-related group, and hospital setting on lipid management in patients with coronary artery disease. <i>American Journal of Cardiology</i> , 2000 , 86, 328-30	3	11
218	Bridging the treatment gap. <i>American Journal of Cardiology</i> , 2000 , 85, 3E-7E	3	74
217	Effect of angiotensin-converting enzyme inhibitor therapy on 30-day outcome in patient > or = 65 years of age with chronic congestive heart failure. <i>American Journal of Cardiology</i> , 2000 , 86, 1151-3, A9	3	6
216	Dyslipidemia, gender, and the role of high-density lipoprotein cholesterol: implications for therapy. <i>American Journal of Cardiology</i> , 2000 , 86, 15L-18L	3	48
215	Clinical treatment of dyslipidemia: practice patterns and missed opportunities. <i>American Journal of Cardiology</i> , 2000 , 86, 62L-65L	3	38
214	The economic burden of heart failure. 2000 , 23, III6-10		160

213	Benefits of lipid-lowering agents in stroke and coronary heart disease: pharmacoconomics. 2000 , 2, 144-50	4
212	PANDORA - Survey of Brazilian cardiologists about cholesterol reduction. 2000 , 75, 289-302	2
211	Stroke prevention: narrowing the evidence-practice gap. 2000 , 54, 1899-906	87
210	Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention. 2000 , 102, 3137-47	647
209	Prevention of coronary heart disease. Part II. Secondary prevention, detection of subclinical disease, and emerging risk factors. 2000 , 46, 1-123	2
208	Nonpharmacologic treatment of heart failure in the elderly. 2000 , 16, 477-88	11
207	Putting prevention into daily practice. 2000 , 84, 267-78	3
206	Cardiac rehabilitation and secondary prevention of coronary heart disease. 2001 , 345, 892-902	551
205	Reflections on cardiovascular risk stratification and prevention. 2001 , 4, 7-8	
204	Myocardial heat shock proteins during the development of heart failure. 2001 , 283, 520-5	53
203	Improved cholesterol management in coronary heart disease patients enrolled in an HMO. 2001 , 23, 29-33	7
202	Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. 2001 , 22, 554-72	628
201	Temporal trends (1986-1997) in cholesterol level assessment and management practices in patients with acute myocardial infarction: a population-based perspective. 2001 , 161, 1521-8	20
200	Transforming exercise-based cardiac rehabilitation programs into secondary prevention centers: a national imperative. 2001 , 21, 263-72	40
199	Diet and drug therapy: a dynamic duo for reducing coronary heart disease risk. 2001 , 3, 507-13	5
198	The current status of primary prevention in coronary heart disease. 2001 , 2, 24-37	5
197	Use of lipid-lowering drugs during 1991-98 in Northern Jutland, Denmark. 2001 , 52, 307-11	25
196	Lipid management among coronary artery disease patients with diabetes mellitus or advanced age. <i>American Journal of Cardiology</i> , 2001 , 87, 646-9, A10	3 35

195	Complete atrioventricular block after valvular heart surgery and the timing of pacemaker implantation. <i>American Journal of Cardiology</i> , 2001 , 87, 649-51, A10	3	76
194	Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). <i>American Journal of Cardiology</i> , 2001 , 87, 819-22	3	408
193	Reply. <i>American Journal of Cardiology</i> , 2001 , 87, 1032-1034	3	1
192	Effectiveness of the electronic medical record in cholesterol management in patients with coronary artery disease (Virtual Lipid Clinic). <i>American Journal of Cardiology</i> , 2001 , 88, 163-5, A5	3	23
191	Comparison of physician-managed lipid-lowering care in patients with coronary heart disease in two time periods (1994 and 1999). <i>American Journal of Cardiology</i> , 2001 , 88, 1417-9, A6	3	5
190	Cholesterol risk management: a systematic examination of the gap from evidence to practice. 2001 , 21, 807-17		39
189	Assessment of hypercholesterolemia control in a managed care organization. 2001 , 21, 818-27		37
188	In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease: the time is now. 2001 , 103, 2768-70		66
187	Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. 2001 , 103, 38-44		188
186	Risk Stratification and Prevention in Chronic Coronary Artery Disease: Use of a Novel Prognostic and Computer-Based Clinical Decision Support System in a Large Primary Managed-Care Group Practice. 2002 , 5, 197-213		1
185	A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). 2002 , 162, 1149-55		204
184	The surveillance of cholesterol management in the cardiac rehabilitation setting. 2002 , 22, 245-50		3
183	[Drug use evaluation of antidiyslipidemic agents at a community hospital in Japan]. 2002 , 122, 499-506		
182	Impact of a targeted intervention on lipid-lowering therapy in patients with coronary artery disease in the hospital setting. 2002 , 162, 468-73		21
181	Identification and treatment of individuals at high risk of coronary heart disease. 2002 , 112 Suppl 8A, 3S-9S		12
180	Reducing the knowledge-practice gap in the management of patients with cardiovascular disease. 2002 , 5, 12-5		11
179	Task force #1--magnitude of the prevention problem: opportunities and challenges. 33rd Bethesda Conference. <i>Journal of the American College of Cardiology</i> , 2002 , 40, 588-603	15.1	62
178	Approaching value in asthma management: the need to integrate clinical and economic research with the basic science. 2002 , 109, S503-10		7

177	Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia. 2002 , 62, 2333-47		59
176	A new reality: achieving cholesterol-lowering goals in clinical practice. 2002 , 2, 5-8; discussion 8-11		16
175	Preventing cardiovascular disease in hypertension: effects of lowering blood pressure and cholesterol. 2002 , 95, 821-6		13
174	Managing hyperlipidemia: current and future roles of HMG-CoA reductase inhibitors. <i>American Journal of Health-System Pharmacy</i> , 2002 , 59, 1173-9; quiz 1180-2	2.2	7
173	Disparities in the diagnosis and pharmacologic treatment of high serum cholesterol by race and ethnicity: data from the Third National Health and Nutrition Examination Survey. 2002 , 162, 929-35		78
172	Usefulness of lipoprotein changes during acute coronary syndromes for predicting postdischarge lipoprotein levels. <i>American Journal of Cardiology</i> , 2002 , 89, 7-11	3	25
171	Need for a moratorium on percutaneous transluminal coronary angioplasty in stable coronary artery disease. <i>American Journal of Cardiology</i> , 2002 , 89, 567-70	3	1
170	Cardiovascular risk management in clinical practice: the Midwest Heart Specialists experience. <i>American Journal of Cardiology</i> , 2002 , 89, 23C-29C; discussion 30C	3	10
169	Combination therapy for elevated low-density lipoprotein cholesterol: the key to coronary artery disease risk reduction. <i>American Journal of Cardiology</i> , 2002 , 90, 8K-20K	3	44
168	Statin therapy after acute myocardial infarction: are we adequately treating high-risk patients?. 2002 , 4, 99-106		10
167	Cholesterol absorption inhibitors: defining new options in lipid management. 2003 , 26, 259-64		15
166	Treating hypercholesterolemia: looking forward. 2003 , 26, I21-8		22
165	The power of statins: Aggressive lipid lowering. 2003 , 26, 25-31		78
164	In-hospital initiation of statin therapy in patients with acute coronary events. 2003 , 5, 394-402		2
163	Management of hyperlipidemia in patients with vascular disease. 2003 , 21, 63-7; quiz 68-9		6
162	Medication reconciliation: a practical tool to reduce the risk of medication errors. 2003 , 18, 201-5		254
161	Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. <i>American Journal of Cardiology</i> , 2003 , 91, 11C-17C; discussion 17C-19C	3	69
160	Outcomes in patients with coronary heart disease who do not undergo lipid testing. <i>American Journal of Cardiology</i> , 2003 , 91, 986-8, A7	3	2

159	Comparison of characteristics of patients with coronary heart disease receiving lipid-lowering therapy versus those not receiving such therapy. <i>American Journal of Cardiology</i> , 2003 , 91, 1352-4	3	2
158	Effectiveness of aggressive management of dyslipidemia in a collaborative-care practice model. <i>American Journal of Cardiology</i> , 2003 , 91, 1427-31	3	9
157	Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. <i>American Journal of Cardiology</i> , 2003 , 92, 79-81	3	92
156	Effective strategies for long-term statin use. <i>American Journal of Cardiology</i> , 2003 , 92, 27i-34i	3	26
155	Myocardial heat shock protein changes in the failing heart following coronary artery ligation. 2003 , 12, 60-5		17
154	Undertreatment of hypercholesterolaemia: a population-based study. 2003 , 55, 389-97		33
153	Development and validation of the hyperlipidemia: attitudes and beliefs in treatment (HABIT) survey for physicians. 2003 , 18, 984-90		9
152	Achievement of low-density lipoprotein cholesterol goals: new strategies to address new guidelines. 2003 , 21, 363-75		5
151	Putting prevention into daily practice. 2003 , 21, 471-82		3
150	Undertreatment of hyperlipidemia in patients with coronary artery disease and heart failure. 2003 , 9, 36-41		27
149	Quality of care for secondary prevention for patients with coronary heart disease: results of the Hastening the Effective Application of Research through Technology (HEART) trial. <i>American Heart Journal</i> , 2003 , 146, 1045-51	4.9	30
148	Undocumented patient information: an impediment to quality of care. 2003 , 114, 211-6		40
147	The relationship between nonfasting and fasting lipid measurements in patients with or without type 2 diabetes mellitus receiving treatment with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 2003 , 25, 1490-7		19
146	Determinants of appropriate lipid management in patients with ischaemic heart disease. Cracovian Program for Secondary Prevention of Ischaemic Heart Disease. 2003 , 91, 15-23		10
145	Patients' achievement of cholesterol targets: a cross-sectional evaluation. 2003 , 25, 339-42		8
144	Cost effectiveness of HMG-CoA reductase inhibitors in the management of coronary artery disease: the problem of under-treatment. <i>American Journal of Cardiovascular Drugs</i> , 2003 , 3, 179-91	4	1
143	Rosuvastatin—a highly effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: review of clinical trial data at 10-40 mg doses in dyslipidemic patients. 2003 , 99, 126-39		39
142	In-hospital initiation of lipid-lowering therapy after coronary intervention as a predictor of long-term utilization: a propensity analysis. 2003 , 163, 2576-82		60

141	Costs of dyslipidemia. 2003 , 3, 273-81		1
140	Trends in lipid management among patients with coronary artery disease: has diabetes received the attention it deserves?. 2003 , 26, 991-7		32
139	Patterns of pharmacotherapy in patients hospitalised for congestive heart failure. 2003 , 5, 195-200		21
138	Under treatment with lipid-lowering drugs of high-risk coronary heart disease patients of the GENICA study. 2003 , 42, 484-90		8
137	Acute coronary syndrome emergency treatment strategies: a rationale and road map for critical pathway implementation. 2003 , 2, 71-87		6
136	In-hospital initiation of cardiovascular protective therapies to improve treatment rates and clinical outcomes: the University of California-Los Angeles, Cardiovascular Hospitalization Atherosclerosis Management Program. 2003 , 2, 61-70		4
135	Determination of lipid profiles and use of statins in patients with ischemic stroke or transient ischemic attack. 2003 , 34, 105-10		31
134	Medication undertreatment in assisted living settings. 2004 , 164, 2031-7		83
133	Dyslipidemias and HMG-CoA reductase inhibitor prescription in heart transplant recipients. 2004 , 38, 1136-41		14
132	Get with the guidelines for cardiovascular secondary prevention: pilot results. 2004 , 164, 203-9		209
131	Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001. 2004 , 255, 494-502		55
130	Population implications of changes in lipid management in patients with coronary heart disease. <i>American Journal of Cardiology</i> , 2004 , 93, 193-5	3	11
129	Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure. <i>American Journal of Cardiology</i> , 2004 , 93, 603-6 ³		63
128	Role of in-hospital initiation of carvedilol to improve treatment rates and clinical outcomes. <i>American Journal of Cardiology</i> , 2004 , 93, 77B-81B	3	7
127	Role of selective cholesterol absorption inhibition in the management of dyslipidemia. 2004 , 6, 52-9		7
126	Combined antihypertensive and lipid-lowering treatment. 2004 , 6, 300-6		4
125	Cardiology management improves secondary prevention measures among patients with coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2004 , 43, 1517-23	15.1	22
124	Strategies to increase HMG-CoA reductase inhibitor use after acute myocardial infarction. 2004 , 21, 583-95		1

123	Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. <i>American Heart Journal</i> , 2004 , 147, 705-13	4.9	125
122	Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. <i>American Heart Journal</i> , 2004 , 148, e4	4.9	38
121	Effect of community pharmacist intervention on cholesterol levels in patients at high risk of cardiovascular events: the Second Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP-plus). 2004 , 116, 130-3		40
120	Are there race/ethnicity differences in outpatient congestive heart failure management, hospital use, and mortality among an insured population?. 2004 , 42, 680-9		27
119	Is lipid-lowering therapy underused by African Americans at high risk of coronary heart disease within the VA health care system?. 2004 , 94, 2112-7		12
118	Prescription drug coverage, health, and medication acquisition among seniors with one or more chronic conditions. 2004 , 42, 1056-65		34
117	A practical and evidence-based approach to cardiovascular disease risk reduction. 2004 , 164, 1490-500		40
116	Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting. 2005 , 111, 488-93		86
115	Achievement of English National Service Framework lipid-lowering goals: pooled data from recent comparative treatment trials of statins at starting doses. 2005 , 59, 1171-7		6
114	Review of efficacy of rosuvastatin 5 mg. 2005 , 59, 92-101		7
113	Estimating cholesterol treatment rates among individuals with multiple risk factors and without coronary heart disease. <i>American Journal of Cardiology</i> , 2005 , 95, 862-4	3	10
112	Rosuvastatin for the treatment of hypercholesterolemia. 2005 , 25, 990-1000		21
111	Achieving cholesterol target in a managed care organization (ACTION) trial. 2005 , 25, 360-71		22
110	Real-World Effectiveness of Lipid-Lowering Therapy in Male and Female Outpatients with Coronary Heart Disease: Relation to Pre-Treatment Low-Density Lipoprotein-Cholesterol, Pre-Treatment Coronary Heart Disease Risk, and other Factors. 2005 , 12, 37-45		16
109	The SaM (Screening and Monitoring) Approach to Cardiovascular Risk-Reduction in Primary Care: Cyclic Monitoring and Individual Treatment of Patients at Cardiovascular Risk using the Electronic Medical Record. 2005 , 12, 56-62		
108	Lipid management in patients with coronary artery disease by a clinical pharmacy service in a group model health maintenance organization. 2005 , 165, 49-54		48
107	National trends in statin use by coronary heart disease risk category. 2005 , 2, e123		94
106	An Assessment of Patient Knowledge and Awareness of Issues Surrounding Cholesterol Risk Management: The Large Gaps in Knowledge of Risk Factors in CVD Represent an Opportunity for Pharmacists. 2005 , 138, 46-51		1

105	The SaM (Screening and Monitoring) approach to cardiovascular risk-reduction in primary care--cyclic monitoring and individual treatment of patients at cardiovascular risk using the electronic medical record. 2005 , 12, 56-62		0
104	Differences in physician compliance with guideline on lipid profile determination within 24 h after acute myocardial infarction. 2005 , 14, 41-5		3
103	LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia. 2005 , 21, 571-8		40
102	Closing the osteoporosis management gap in primary care: a secondary prevention of fracture programme. 2005 , 21, 475-82		31
101	Physician attitudes regarding cardiovascular risk reduction: the gaps between clinical importance, knowledge, and effectiveness. 2005 , 8, 93-105		24
100	Real-world effectiveness of lipid-lowering therapy in male and female outpatients with coronary heart disease: relation to pre-treatment low-density lipoprotein-cholesterol, pre-treatment coronary heart disease risk, and other factors. 2005 , 12, 37-45		2
99	Lipids and CVD management: towards a global consensus. 2005 , 26, 2224-31		66
98	Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2005 , 45, 1003-12	15.1	109
97	National study of physician awareness and adherence to cardiovascular disease prevention guidelines. 2005 , 111, 499-510		548
96	Achieving National Cholesterol Education Program goals in coronary artery disease. 2005 , 8, 18-22		
95	Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial. <i>American Heart Journal</i> , 2005 , 149, 444-50	4.9	25
94	Managed care patients with heart failure: spectrum of ventricular dysfunction and predictors of medication utilization. 2005 , 11, 106-11		8
93	Impact of Coaching Patients on Coronary Risk Factors. 2005 , 13, 225-244		12
92	The Performance Gap between Clinical Trials and Patient Treatment for Dyslipidemia. 2005 , 13, 255-265		3
91	Effectiveness of Interventions to Increase Adherence to Statin Therapy. 2005 , 13, 73-82		2
90	Clinical Outcomes Associated with Pharmacist Involvement in Patients with Dyslipidemia. 2005 , 13, 31-42		8
89	An Evaluation of the Factors Associated with Statin Dose Management and Low-Density Lipoprotein-Cholesterol Goal Attainment. 2006 , 14, 37-44		2
88	Evaluation of lipid-lowering therapy and cholesterol goal attainment in Finland: the National FINRISK Study. <i>American Journal of Cardiovascular Drugs</i> , 2006 , 6, 349-55	4	14

87	The A-SACT (Achievement in Singapore of Cholesterol Targets) study in patients with coronary heart disease. <i>American Journal of Cardiovascular Drugs</i> , 2006 , 6, 383-91	4	20
86	Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium. 2006 , 113, 647-56		235
85	Clinical inertia: Overcoming a major barrier to diabetes management. 2006 , 1, 61-64		4
84	Efectividad de un programa de prevención secundaria de la arteriosclerosis en el control de las dislipemias en pacientes con enfermedad arterial coronaria. 2006 , 18, 128-136		
83	Metabolic syndrome and the risk of cardiovascular disease in older adults. <i>Journal of the American College of Cardiology</i> , 2006 , 47, 1595-602	15.1	152
82	Disease management in heart failure. 2006 , 12, e58-69		13
81	Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapy (MERCURY) II. <i>American Heart Journal</i> , 2006 , 151, 975.e1-9	4.9	69
80	Quality of cholesterol screening and management with respect to the National Cholesterol Education® Third Adult Treatment Panel (ATPIII) guideline in primary care practices in North Carolina. <i>American Heart Journal</i> , 2006 , 152, 785-92	4.9	14
79	Treatment Gap in the Management of Hypercholesterolemia in Korea: Return on Expenditure Achieved for Lipid Therapy (REALITY). 2006 , 36, 593		10
78	Cardiac Rehabilitation. 2006 , 461-507		0
77	Hospital discharge treatments after an acute event: evidence for a systems approach to prevention. 2006 , 17, 239-41		3
76	The impact of physician attitudes and beliefs on treatment decisions: lipid therapy in high-risk patients. 2006 , 44, 421-8		19
75	Dyslipidemia in menopause: mechanisms and management. 2006 , 61, 608-13		14
74	Quality of cardiovascular disease preventive care and physician/practice characteristics. 2006 , 21, 231-7		43
73	Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents. <i>American Journal of Cardiology</i> , 2006 , 98, 1231-3		20
72	The association between processes, structures and outcomes of secondary prevention care among VA ischemic heart disease patients. 2006 , 6, 6		3
71	Lipid assessment and treatment patterns in hospitalized TIA and ischemic stroke patients. 2006 , 1, 214-20		13
70	The MERCURY II trial: benefits of rosuvastatin. 2006 , 6, 171-176		1

69	Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. 2006 , 22, 2041-53		91
68	Clinical pharmacy cardiac risk service for managing patients with coronary artery disease in a health maintenance organization. <i>American Journal of Health-System Pharmacy</i> , 2007 , 64, 77-84	2.2	25
67	Lipid management in ischemic stroke patients. 2007 , 109, 758-62		1
66	Achievement of guideline-defined treatment goals in primary care: the German Coronary Risk Management (CoRiMa) study. 2007 , 28, 3051-8		27
65	Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial. 2007 , 82, 543-50		29
64	Lipid-modifying therapy and attainment of cholesterol goals in Hungary: the return on expenditure achieved for lipid therapy (REALITY) study. 2007 , 27, 647-60		13
63	LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO. 2007 , 13, 652-63		31
62	Initiation of statins after hospitalization for coronary heart disease. 2007 , 13, 385-96		15
61	Prevention of sudden cardiac death. 449-462		
60	Patterns and predictors of statin use after coronary artery bypass graft surgery. 2007 , 134, 932-8		43
59	Rosuvastatin: The Most Efficient Treatment Option For Patients With Dyslipidemia. 2007 , 2, 127-141		
58	Reinforcing a continuum of care: in-hospital initiation of long-term secondary prevention following acute coronary syndromes. 2007 , 21, 375-88		11
57	Adherence to best practices: How do patient race and gender affect physician performance?. 2007 , 1, 102-107		0
56	Effect of an educational program (PEGASE) on cardiovascular risk in hypercholesterolaemic patients. 2008 , 22, 495-505		13
55	Cholesterol goal attainment in patients with coronary heart disease and elevated coronary risk: results of the Hong Kong hospital audit study. 2008 , 11 Suppl 1, S91-8		18
54	Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia. 2008 , 28, 570-5		8
53	Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme. 2008 , 28, 625-34		33
52	ACC/AHA 2008 performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for ST-Elevation and Non-ST-Elevation Myocardial Infarction). Developed in Collaboration With the American Academy of Family Physicians and American College of Emergency Physicians Endorsed by the American Association of Cardiovascular and Pulmon. <i>Journal of the American College of Cardiology</i> , 2008 , 52, 2046-99	15.1	152

51	National improvements in low-density lipoprotein cholesterol management of individuals at high coronary risk: National Health and Nutrition Examination Survey, 1999 to 2002. <i>American Heart Journal</i> , 2008 , 156, 284-91	4.9	11
50	Increased adherence to cardiac standards of care during participation in cardiac disease management programs. 2008 , 11, 111-8		6
49	ACC/AHA 2008 performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to develop performance measures for ST-elevation and non-ST-elevation myocardial infarction): developed in collaboration with the Quality of lipid management in outpatient care: a national study using electronic health records. 2008 , 23, 375-81 American Association of Cardiovascular and. 2008 , 118, 2596-648		167
48	Changes in lipid profile of patients referred to a cardiac rehabilitation program. 2008 , 15, 467-72		9
47	The effect of a disease management algorithm and dedicated postacute coronary syndrome clinic on achievement of guideline compliance: results from the parkland acute coronary event treatment study. 2008 , 56, 15-25		23
46	Effect of an intervention to increase statin use in medicare members who qualified for a medication therapy management program. 2008 , 14, 532-40		3
45	Impact of decision support in electronic medical records on lipid management in primary care. 2009 , 12, 221-6		6
44	Appropriateness of cholesterol management in primary care by sex and level of cardiovascular risk. 2009 , 12, 95-101		22
43	Defining and measuring physicians' responses to clinical reminders. 2009 , 42, 317-26		22
42	Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. 2009 , 25, 2755-64		32
41	Closing the heart failure management gap in the community: managing hypotension and impact on outcomes. 2009 , 15, 906-11		62
40	Prevalence and predictors of lipid abnormalities in patients treated with statins in the UK general practice. 2009 , 202, 225-33		3
39	Improving outcomes in high-risk populations using REACH: an inpatient cardiac risk reduction program. 2009 , 8, 112-8		21
38	Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. 2010 , 21, 492-8		2
37	Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies. 2010 , 33, 609-619		77
36	Evidence for the insufficient evaluation and undertreatment of chronic hepatitis B infection in a predominantly low-income and immigrant population. 2010 , 25, 369-75		5
35	Randomized Trial of a Pharmacist-Delivered Intervention for Improving Lipid-Lowering Medication Adherence among Patients with Coronary Heart Disease. 2010 , 2010, 383281		27
34			23

33	Attainment of low-density lipoprotein cholesterol goals in coronary artery disease. 2010 , 4, 173-80		28
32	Trends in hypercholesterolemia, treatment and control among United States adults. 2010 , 140, 226-35		126
31	Section 8: Disease Management, Advance Directives, and End-of-Life Care in Heart Failure Education and Counseling. 2010 , 16, e98-e114		2
30	Are quality improvements associated with the Get With the Guidelines-Coronary Artery Disease (GWTG-CAD) program sustained over time? A longitudinal comparison of GWTG-CAD hospitals versus non-GWTG-CAD hospitals. <i>American Heart Journal</i> , 2010 , 159, 207-14	4.9	34
29	Extent of control of cardiovascular risk factors and adherence to recommended therapies in US multiethnic adults with coronary heart disease: from a 2005-2006 national survey. <i>American Journal of Cardiovascular Drugs</i> , 2010 , 10, 109-14	4	20
28	Influence of patients' coronary artery calcium on subsequent medication use patterns. <i>American Journal of Health Behavior</i> , 2012 , 36, 628-38	1.9	3
27	High performance liquid chromatography mass spectrometric method for the simultaneous quantification of pravastatin and aspirin in human plasma: Pharmacokinetic application. <i>Journal of Pharmaceutical Analysis</i> , 2012 , 2, 206-213	14	21
26	Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 1401-8	15.1	193
25	Hemmung der Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). <i>CardioVasc</i> , 2013 , 13, 44-48	0	
24	Lipid-lowering treatment in patients at high cardiovascular risk discharged from an Italian hospital. <i>Journal of Cardiovascular Medicine</i> , 2013 , 14, 270-5	1.9	1
23	Intensive nursing care by an electronic followup system to promote secondary prevention after percutaneous coronary intervention: a randomized trial. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2014 , 34, 396-405	3.6	5
22	Combined Effects of Rosuvastatin and Exercise on Gene Expression of Key Molecules Involved in Cholesterol Metabolism in Ovariectomized Rats. <i>PLoS ONE</i> , 2016 , 11, e0159550	3.7	8
21	Pharmacist prescribing practices in a clinical pharmacy cardiac risk service. <i>American Journal of Health-System Pharmacy</i> , 2016 , 73, 1442-50	2.2	7
20	Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids. <i>Clinical Pharmacology and Therapeutics</i> , 2016 , 99, 59-71	6.1	8
19	Primary Prevention Using Cholesterol-Lowering Medications in Patients Meeting New Treatment Guidelines: A Retrospective Cohort Analysis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018 , 24, 1078-1085	1.9	3
18	A new paradigm of cardiovascular risk factor modification. <i>Vascular Health and Risk Management</i> , 2005 , 1, 101-9	4.4	3
17	Risk Evaluation in Action for Cardiovascular Health. <i>Critical Care Nurse</i> , 2005 , 25, 26-37	1.6	13
16	Gender outcomes in acute myocardial infarction: are women from Venus and men from Mars?. <i>EuroIntervention</i> , 2011 , 6, 1029-31	3.1	3

15	Gender disparities in optimal lipid control among patients with coronary artery disease. <i>Journal of Atherosclerosis and Thrombosis</i> , 2014 , 21 Suppl 1, S20-8	4	16
14	Collaborative cardiac care service: a multidisciplinary approach to caring for patients with coronary artery disease. 2008 , 12, 4-11		16
13	Ambulatory treatment gaps in patients with ischemic stroke or transient ischemic attack. 2013 , 17, 28-34		1
12	Outpatient Therapy. <i>Developments in Cardiovascular Medicine</i> , 2000 , 149-200		
11	Abnormal blood lipids. Foreword. <i>Journal of Cardiovascular Nursing</i> , 2000 , 14, v-vii	2.1	
10	Nutritional Issues of Cardiovascular Disease in Women. <i>Modern Nutrition</i> , 2003 , 257-293		
9	Tratamiento de la insuficiencia cardíaca congestiva. 2006 , 167-174		
8	The Epidemiology and Etiology of Atherosclerosis. 2006 , 1-8		
7	Cardiac Rehabilitation: Statins and the Rationale for Implementation of Lipid-Lowering Therapy. 2007 , 141-156		
6	Cardiac Rehabilitation. 2007 , 1113-1132		
5	Cholesterol levels and statin use in patients with coronary heart disease treated in primary care settings. <i>Preventing Chronic Disease</i> , 2005 , 2, A05	3.7	3
4	Hypertension and medical informatics. <i>Journal of the National Medical Association</i> , 2003 , 95, 1048-56	2.3	6
3	Missed opportunity in the treatment of hyperlipidemia in patients with coronary heart disease: the primary care setting. <i>Journal of the National Medical Association</i> , 2006 , 98, 58-62	2.3	3
2	General practitioners' adherence with clinical reminders for secondary prevention of dyslipidemia. 2007 , 766-70	0.7	1
1	National Trends and Disparities in Statin Use for Ischemic Heart Disease from 2006 to 2018: Insights from National Ambulatory Medical Care Survey. <i>American Heart Journal</i> , 2022 ,	4.9	0